Over the past decades, tremendous advances have been made in pharmacotherapies for breast cancer, especially in targeted therapy, reducing the 10-year risk of dying from breast cancer by 6.4% in patients diagnosed with early HER2-positive breast cancer (2, 25). This evidence concerns the gene ERBB2 and breast carcinoma.